Eli Lilly and Company Stock price

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 21:00:02 06/12/2023 GMT Intraday chart for Eli Lilly and Company 5-day change 1st Jan Change
589.25 USD +0.19% -0.44% +61.07%
Sales 2023 * 33.6B 2,673B Sales 2024 * 38.84B 3,090B Capitalization 530B 42,158B
Net income 2023 * 5.29B 421B Net income 2024 * 10.69B 850B EV / Sales 2023 *
16,2x
Net Debt 2023 * 14.19B 1,129B Net Debt 2024 * 11.73B 933B EV / Sales 2024 *
13,9x
P/E ratio 2023 *
98,9x
P/E ratio 2024 *
48,3x
Employees 39,000
Yield 2023 *
0,74%
Yield 2024 *
0,87%
Free-Float 99.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.19%
1 week-0.44%
Current month-0.30%
1 month-1.00%
3 months+5.23%
6 months+32.99%
Current year+61.07%
More quotes
1 week
574.33
Extreme 574.33
601.97
1 month
574.33
Extreme 574.33
625.87
Current year
302.14
Extreme 302.14
629.97
1 year
302.14
Extreme 302.14
629.97
3 years
146.91
Extreme 146.91
629.97
5 years
101.36
Extreme 101.36
629.97
10 years
48.88
Extreme 48.88
629.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 1995
Director of Finance/CFO 50 2013
Compliance Officer - 1996
Members of the board TitleAgeSince
Director/Board Member 62 2021
Director/Board Member 67 2009
Director/Board Member 64 2004
More insiders
Date Price Change Volume
06/12/23 589.25 +0.19% 2,093,105
05/12/23 588.15 +0.42% 2,157,343
04/12/23 585.68 +0.28% 2,577,122
01/12/23 584.04 -1.18% 3,638,565
30/11/23 591.04 -0.14% 5,658,350

Delayed Quote Nyse, December 06, 2023 at 09:00 pm

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (46.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (20.3%); - immunology diseases (11.8%); - neurology (6.7%): primarily drugs used in treating depression and schizophrenia; - other (14.6%). Net sales are distributed geographically as follows: the United States (59.4%), Europe (16.9%), Japan (8.3%), China (5.9%) and other (9.5%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
589.25USD
Average target price
619.14USD
Spread / Average Target
+5.07%
Consensus
1st Jan change Capi.
+61.07% 530 B $
+44.35% 438 B $
-11.34% 377 B $
-4.79% 268 B $
-9.42% 258 B $
+0.98% 200 B $
-9.65% 198 B $
-43.81% 163 B $
+2.55% 144 B $
-4.20% 117 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Eli Lilly and Company - Nyse
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer